Debt-to-equity in % of AbCellera Biologics Inc. from Q3 2021 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
AbCellera Biologics Inc. quarterly Debt-to-equity history and change rate from Q3 2021 to Q3 2025.
  • AbCellera Biologics Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 34.9 %, a 21.3% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

AbCellera Biologics Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 34.9 +6.13 +21.3% 30 Sep 2025
Q2 2025 32.1 +3.66 +12.9% 30 Jun 2025
Q1 2025 29.1 +0.33 +1.15% 31 Mar 2025
Q4 2024 28.7 +1.29 +4.71% 31 Dec 2024
Q3 2024 28.7 +2.42 +9.19% 30 Sep 2024
Q2 2024 28.4 +3 +11.8% 30 Jun 2024
Q1 2024 28.8 +2.67 +10.2% 31 Mar 2024
Q4 2023 27.4 -0.68 -2.42% 31 Dec 2023
Q3 2023 26.3 -2.65 -9.15% 30 Sep 2023
Q2 2023 25.4 -3.64 -12.5% 30 Jun 2023
Q1 2023 26.1 +0.08 +0.31% 31 Mar 2023
Q4 2022 28.1 +5.82 +26.2% 31 Dec 2022
Q3 2022 29 +8.75 +43.3% 30 Sep 2022
Q2 2022 29.1 30 Jun 2022
Q1 2022 26 31 Mar 2022
Q4 2021 22.2 31 Dec 2021
Q3 2021 20.2 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.